Oxford Science Enterprises portfolio company MiroBio will be acquired by Gilead Sciences for approximately 5 million

Oxford Science Enterprises portfolio company MiroBio will be acquired by Gilead Sciences for approximately $405 million

OXFORD, England, August 4, 2022 /PRNewswire/ — Oxford Science Enterprises (OSE), the independent investment firm created to found, finance and build transformative businesses through its unique partnership with Oxford Universityis pleased to announce that life sciences portfolio company MiroBio will be acquired by global biopharmaceutical company Gilead Sciences for approximately 405 million dollars in cash, subject to the usual adjustments.

MiroBio was separated from Oxford University in 2019 to develop a new class of drugs called immune checkpoint agonists to treat autoimmune diseases by rebalancing the immune system. The company was co-founded by OSE and Tim Funnell, OSE’s resident entrepreneur at the time, and Samsara BioCapital, working closely with MiroBio’s scientific founders – Simon DaviesProfessor of Molecular Immunology, MRC Weatherall Institute of Molecular Medicine, and Richard CornallNuffield Professor of Clinical Medicine.

OSE has supported MiroBio since its inception, providing strategic and operational support as well as funding. OSE co-led MiroBio’s £27 million Series A investment with Samsara BioCapital in 2019, bringing in several other premier global life science investors. The company also participated in MiroBio’s recent £80m Series B round led by Medicxi, further strengthening its global investor base.

Following its acquisition by Gilead, MiroBio will continue its operations in Oxford, UK.

Katya Smirnyagina, Senior Partner, Life Sciences at OSE, said: “OSE is proud to have played a key role in the creation of MiroBio and to have supported its successful development until its acquisition by Gilead. Combining MiroBio’s innovative technology with that of a world-leading company should allow its pipeline to truly flourish. This is a great example of our model in action where OSE works with leads Oxford academics to direct their groundbreaking science on a trajectory where it can have a positive impact—in this case, developing much-needed new therapies for patients with debilitating autoimmune diseases. We are delighted with the outcome, not only for the founders and everyone at MiroBio, but also because it provides us with a strong return on our investment, providing additional funds to reinvest in Oxford spinouts.”

The closing of the transaction is subject to the expiration or termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act and other customary conditions.

See the full press release on the Gilead news page

About Oxford Science Enterprises

Oxford Science Enterprises (OSE) is a multi-billion pound independent investment firm established in 2015 to found, finance and build transformative businesses through its unique partnership with Oxford University#1 research university in the world.

This partnership enables OSE to work with the brightest academic minds tackling the world’s toughest challenges and ensures unrivaled access to their research. In collaboration with its global network of entrepreneurs and advisors, OSE shapes and nurtures complex ideas into successful businesses while pursuing attractive returns for shareholders.

Actively focused on a core portfolio of around 40 companies spanning three high-growth, high-impact sectors – Life Sciences, Health Tech and Deep Tech – the company adopts a flexible, long-term investment approach, recognizing the path from pioneering to exploring global markets requires time and resilience.

To date, OSE has invested £0.5bn in over 80 ambitious companies built on them Oxford science.

A key player in of Oxford entrepreneurial ecosystem, OSE is highly motivated to foster an environment that catalyzes pioneering research and guides it to commercial success.

Learn more: oxfordscienceenterprises.com | Twitter | LinkedIn

About MiroBio

MiroBio is a private, clinical-stage biotechnology company whose mission is to develop a new class of therapeutic agents, checkpoint agonist antibodies, to restore immune balance in autoimmune patients. MiroBio has developed I-ReSToRE, a proprietary discovery platform combining its Checkpoint Atlas™, a cutting-edge receptor mapping database and visualization tool, with proprietary antibody engineering. I turned from Oxford University in 2019 and is based on more than 15 years of seminal research from the laboratories of Prof. Simon Davies and professor Richard Cornall with the potential to create safer and more effective drugs for patients with autoimmune diseases. MiroBio is backed by a strong group of international investors, including Oxford Science Enterprises, Samsara BioCapital, SR One, Medixci, Advent Life Sciences, OrbiMed and Monograph.

For more information about MiroBio, please visit the company’s website: https://www.mirobio.com/

Contacts:

Oxford Science Enterprises
Lisa Bedwell[email protected]

For media inquiries:
Mark Swallow, Sandy Greenwood, Eleanor Perkin – MEDiSTRAVA Consulting
[email protected]
+44 (0)203 928 6900

SOURCE Oxford Science Enterprises

Leave a Comment

Your email address will not be published.